

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATION

In re Application of:

Chen et al.Serial No.: **Not Yet Assigned**

Group Art Unit: --

Filed: **Concurrently Herewith**

Examiner: --

For: **OMEPRAZOLE FORMULATION**

New York, NY 10036

March 19, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT**

Sir:

The following statement of relevance is submitted with the accompanying
Form PTO/SB/08A.Document
DesignationAA
U.S.P. 4,045,563RelevanceRelates to a substituted 2-[pyridylalkylenesulfinyl]-ben-
zimidazoles with gastric acid secretion inhibiting effects.AB
U.S.P. 4,045,564Relates to benzimidazole derivatives useful as gastric acid
secretion inhibitors.AC
U.S.P. 4,182,766

Relates to naph[2,3-d]imidazoles.

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on March 19, 2004

Martin P. Endres, Reg. No. 35,498

<u>Document Designation</u>	<u>Relevance</u>
AD U.S.P. 4,255,431	Relates to a gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion.
AE U.S.P. 4,337,257	Relates to gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparations containing same, and method for inhibiting gastric acid secretion.
AF U.S.P. 4,359,465	Relates to methods for treating gastrointestinal inflammation.
AG U.S.P. 4,432,966	Relates to compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating.
AH U.S.P. 4,508,905	Relates to substituted 2-(benzimidazolyl) pyridines.
AI U.S.P. 4,544,750	Relates to certain pyridyl-N-oxide intermediates for the preparation of omeprazole.
AJ U.S.P. 4,620,008	Relates to processes for the preparation of omeprazole and intermediates therefore.
AK U.S.P. 4,636,499	Relates to sulphenamides.
AL U.S.P. 4,686,230	Relates to a picoline derivatives useful as gastric acid secretion inhibitors.
AM U.S.P. 4,738,974	Relates to base addition salts of omeprazole.
AN U.S.P. 4,786,505	Relates to a new pharmaceutical preparation for oral use containing omeprazole.
AO U.S.P. 4,840,799	Relates to a process for preparing rapidly disintegrating particles.
AP U.S.P. 4,853,230	Relates to pharmaceutical formulations of acid labile substances for oral use.
AQ U.S.P. 5,045,321	Relates to a stabilized pharmaceutical composition and its production.

AR U.S.P. 5,093,132	Relates to a stabilized pharmaceutical composition and its production.
AS U.S.P. 5,093,342	Relates to the use of omeprazole as an antimicrobial agent.
AT U.S.P. 5,178,867	Relates to a dosage form for delivering drug in short time period.
AU U.S.P. 5,204,118	Relates to pharmaceutical compositions and methods for treating the symptoms of indulgence.
AV U.S.P. 5,244,670	Relates to an ingestible pharmaceutical composition for treating upper gastrointestinal tract distress.
AW U.S.P. 5,288,506	Relates to antacid compositions with prolonged gastric residence time.
AX U.S.P. 5,304,540	Relates to pharmaceutical compositions and methods for using the same.
AY U.S.P. 5,330,982	Relates to a pharmaceutical composition containing a 5 HT receptor antagonist and a method of treating gastrointestinal disorders therewith.
AZ U.S.P. 5,352,688	Relates to a method for the treatment of bradyphrenia in Parkinson's disease.
BA U.S.P. 5,362,424	Relates to a microencapsulation for controlled oral drug delivery system.
BB U.S.P. 5,385,739	Relates to stable compositions of gastroprotected omeprazole microgranules and process for the production thereof.
BC U.S.P. 5,389,664	Relates to alleviating stomach ulcers in swine.
BD U.S.P. 5,399,700	Relates to method for preparing enteric coated oral drugs containing acid unstable compounds.
BE U.S.P. 5,417,980	Relates to pharmaceutical compositions and methods for treating the symptoms of overindulgence.
BF U.S.P. 5,433,959	Relates to a stabilized pharmaceutical composition.
BG U.S.P. 5,508,041	Relates to microencapsulation for controlled oral drug delivery system.

BH U.S.P. 5,518,730	Relates to a biodegradable controlled release flash flow melt spun delivery system.
BI U.S.P. 5,599,794	Relates to a synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
BJ U.S.P. 5,620,964	Relates to compositions for treating and inhibiting gastric and duodenal ulcers.
BK U.S.P. 5,622,717	Relates to ulcer prevention using a melt spun hydrogel.
BL U.S.P. 5,637,320	Relates to a controlled absorption naproxen formulation for once-daily administration.
BM U.S.P. 5,639,478	Relates to a method to stabilize a pharmaceutical composition and its production.
BN U.S.P. 5,693,818	Relates to a process for preparing pure salts of pyridinylmethyl-sulfinyl-1h-benzimidazole.
BO U.S.P. 5,753,265	Relates to a multiple unit pharmaceutical preparation.
CA WO 85/03436	Relates to diffusion coated multiple units dosage form.
CB WO 95/01783	Relates to a new pharmaceutical formulation.
CC WO 95/10264	Relates to a tablet containing enteric granules.
CD WO 95/12590	Relates to a preparation of omeprazole and lansoprazole and intermediates useful therein.
CE WO 96/01612	Relates to a novel drug delivery system.
CF WO 96/01622	Relates to a new oral pharmaceutical formulation containing magnesium salt of omeprazole.
CG WO 96/01623	Relates to multiple unit tableted dosage form.
CH WO 96/24375	Relates to a new pharmaceutical dosage form.

CI WO 96/02535	Relates to a process for synthesis of substituted sulfoxides.
CJ CA 1,127,158	Relates to 2-pyridymethylsulfinyl-benzimidazole compounds.
CK CA 1,129,417	Relates to gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion.
CL CA 1,234,118	Relates to pyridyl-n-oxide intermediates for the preparation of omeprazole.
CM CA 1,263,119	Relates to production of 2-(2 pyridylmethylsulfinyl) benzimidazole compounds.
CN CA 1,264,751	Relates to base addition salts of omeprazole.
CO CA 1,292,693	Relates to a pharmaceutical preparation containing omeprazole.
CP CA 1,302,891	Relates to pharmaceutical formulations of acid labile substances for oral use.
CQ CA 1,324,758	Relates to transdermal antisecretory agents for gastrointestinal disease.
CR CA 1,338,377	Relates to stabilized pharmaceutical composition and its production.
CS CA 2,037,101	Relates to omeprazole compositions designed for administration in rectum.
CT CA 2,046,364	Relates to galenic process for omeprazole containing pellets.
CU CA 2,083,605	Relates to method for synthesis.
CV CA 2,139,653	Relates to optically pure salts of pyrinylmethyl sulfinyl-1H-benzimidazole compounds.
CW CA 2,140,347	Relates to injection and injection kit containing omeprazole and it analogs.
CX CA 2,166,483	Relates to a new pharmaceutical formulation.

CY CA 2,166,794	Relates to magnesium omeprazole.
CZ CA 2,170,647	Relates to multiple unit tableted dosage form.
DA CA 2,193,681	Relates to a new oral pharmaceutical containing magnesium salt of omeprazole.
DB GB 1,234,058	Relates to pyridylalkyloxy and pyridylalkythioazole derivatives.
DC EPO 124,495	Relates to omeprazole salts.
EA L. Olbe, S.E. et al., Present Situation and Future Prospects of Medical Treatment., <u>Gastrins and the Vagus</u> , Academic Press p. 245-250, 1979.	Relates to omeprazole.
EB Ekenved et al. "Studies with H 168/68, a Novel Gastric Acid Secretion Inhibitor., <u>Gut</u> , Vol. 22, No. 10, October 1981 p. A877.	Relates to omeprazole.
EC Erik Fellenius et al., Substituted Benzimidazoles Inhibit Gastric Acid Secretion by Blocking (H ⁺ + K ⁺) ATPase., <u>Nature</u> , Vol. 290, March 12, 1981 p. 159-161	Relates to omeprazole.
ED Tore Lind, et al., Effect of Omeprazole – A Gastric Proton Pump Inhibitor on Pentagastrin Stimulated Acid Secretion in Man., <u>Gut</u> , Vol. 24 p. 270-276, 1983.	Relates to omeprazole.
EE K-Fr Sewin et al., Effect of Substituted Benzimidazoles on Acid Secretion in Isolated and Enriched Guinea Pig Parietal Cells., <u>Gut</u> , Vol. 24 p. 557-560, June 1983.	Relates to omeprazole.


- EF
Haken Larsson et al., Inhibition of Gastric Acid Secretion by Omeprazole in the Dog and the Rat. Gastroenterology, Vol. 85 p. 900-907, October 1983. Relates to omeprazole.
- EG
Walter Londong et al. Dose-Response Study of Omeprazole on Meal-Stimulated Gastric Acid Secretion and Gastrin Release., Gastroenterology, Vol. 85 p. 1373-1378, December 1983. Relates to omeprazole.
- EH
Stanislaw J. et al., Effects of Omeprazole, a Substituted Benzimidazole, on Gastrointestinal Secretions, Serum Gastrin and Gastric Mucosal Blood Flow on Dogs. Gastroenterology, Vol. 86, p. 71-77, January 1984. Relates to omeprazole.
- EI
D.A. Henry et al., Omeprazole: Effects on Oxidative Drug Metabolism., British Journal of Clinical Pharmacology, Vol. 18, p. 195-200, August 1984. Relates to omeprazole.
- EJ
B.K. Sharma et al., Optimal Dose of Oral Omeprazole for Maximal 24 Hour Decrease of Intragastric Acidity. Gut, Vol. 25 p. 957-964, September 1984. Relates to omeprazole.
- EK
H.P.M. Festen et al., Effect of Oral Omeprazole on Serum Gastrin and Serum Pepsinogen I Levels. Gastroenterology, Vol 87 p. 1030-1034, November 1984. Relates to omeprazole.
- EL
Peter Prichard et al. Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosages Gastroenterology, Vol. 88 pp. 64-69 January 1985. Relates to omeprazole.

EM	Relates to omeprazole.
K.O. Borg and L. Olbe, Omeprazole – A Survey of Preclinical Data, <u>Gastroenterology</u> , p. 15-22, 37-51, 71-77, 79-93, 105-120, June 1985.	
EN	Relates to omeprazole.
50 th Edition of Physician's, 1996 Desk Reference p. 529—531.	
EO	Relates to omeprazole.
K.O. Borg, L. Olbe Proceedings of the First International Symposium on Omeprazole, Supplement to the <u>Scandinavian Journal of Gastroenterology</u> , pp. 11-17, 31-38, 54-56, 59-60, 75-76, 77-78, 89-91, 92-98, 99-104, 105-135, 179, 182-183, 187-195, 1996.	
FA	Relates to omeprazole formulations.
U.S.P. 6,096,340	
FB	Relates to a new pharmaceutical formulation and process.
WO 96/24338	
FC	Relates to an oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production.
EP 1010423 A2	
FD	Relates to omeprazole formulation.
September 23, 1994 Decision of the Korean Patent Office Regarding Korean Patent No. 55426 with Certified English Translation See page 4, line 13 to page 5, line 8.	
FE	Relates to omeprazole formulation.
Korean Patent Application 92-17571 with Certified English Translation	

Full text copies or abstracts of the above-identified reference were previously supplied in application Serial No. 09/763,831. Pursuant to 37 C.F.R. 1.98 (d) copies of references AA-FE are not provided with this Information Disclosure Statement because copies of these references were supplied in the parent application, Serial No. 09/763,831. If additional copies are needed, the Examiner is invited to telephone the undersigned and copies will be immediately provided.

It is respectfully requested that this art be considered by the Examiner in the above-entitled application and made of record therein. It is believed that no fee is required for submission of this Information Disclosure Statement under 37 C.F.R. §1.97(b). However, if a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 08-1540.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Martin P. Endres', is written over a horizontal line.

Martin P. Endres
Reg. No. 35,498

MAILING ADDRESS:
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036
(212) 302-8989

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Chih-Ming Chen
		Art Unit	
		Examiner Name	
Sheet 1 of 7	Attorney Docket Number	141-201B	

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	us- 4,045,563	08-30-1977	Berntsson et al.	
	AB	us-4,045,564	08-30-1977	Berntsson et al.	
	AC	us-4,182,766	01-08-1980	Krasso et al.	
	AD	us-4,255,431	03-10-1981	Junggren et al.	
	AE	us-4,337,257	06-29-1982	Junggren et al.	
	AF	us- 4,359,465	11-16-1982	Ruwart	
	AG	us- 4,432,966	02-21-1984	Zeitoun et al.	
	AH	us- 4,508,905	04-02-1985	Junggren et al.	
	AI	us- 4,544,750	10-01-1985	Brandstrom et al.	
	AJ	us- 4,620,008	10-28-1986	Brandstrom et al.	
	AK	us- 4,636,499	01-13-1987	Brandstrom et al.	
	AL	us- 4,686,230	08-11-1987	Rainer et al.	
	AM	us- 4,738,974	04-19-1988	Brandstrom et al.	
	AN	us-4,786,505	11-22-1988	Lovgren et al.	
	AO	us-4,840,799	06-20-1989	Appeigren et al.	
	AP	us- 4,853,230	08-01-1989	Lovgren et al.	
	AQ	us-5,045,321	09-03-1991	Makino et al.	
	AR	us- 5,093,132	03-03-1992	Makino et al.	
	AS	us- 5,093,342	03-03-1992	Tomoi et al.	
	AT	us- 5,178,867	01-12-1993	Guittard et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)				
	CA	WO	85/03436	08-15-1985	Kjorn et al.		
	CB	WO	95/01783	01-19-1995	Bengtsson et al.		
	CC	WO	95/10264	04-20-1995	Naoyuki et al.		
	CD	WO	95/12590	05-11-1995	Slemon		
	CE	WO	96/01612	01-25-1996	Veronesi		
	CF	WO	96/01622	01-25-1996	Bengtsson et al.		
	CG	WO	96/01623	01-25-1996	Bergstrand et al.		
	CH	WO	96/24375	08-15-1996	Depui et al.		
	CI	WO	96/02535	02-01-1996	Larsson et al.		
	CJ	CA	1,127,158	07-06-1985	Junggren et al.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Chih-Ming Chen
		Art Unit	
		Examiner Name	
Sheet 2 of 7	Attorney Docket Number	141-201B	

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AU	us- 5,204,118	04-20-1993	Goldman et al.	
	AV	us- 5,244,670	09-14-1993	Upson et al.	
	AW	us- 5,288,506	02-22-1994	Spickett et al.	
	AX	us- 5,304,540	04-19-1994	Blackburn et al.	
	AY	us- 5,330,982	07-19-1994	Tyers	
	AZ	us- 5,352,688	10-04-1994	Kaminski	
	BA	us- 5,362,424	11-08-1994	Lee et al.	
	BB	us- 5,385,739	01-31-1995	Debregeas et al.	
	BC	us- 5,389,664	02-14-1995	Biale et al.	
	BD	us- 5,399,700	03-21-1995	Min et al.	
	BE	us- 5,417,980	05-23-1995	Goldman et al.	
	BF	us- 5,433,959	07-18-1995	Makino et al.	
	BG	us- 5,508,041	04-16-1996	Lee et al.	
	BH	us- 5,518,730	05-21-1996	Fuisz	
	BI	us- 5,599,794	02-04-1997	Eek et al.	
	BJ	us- 5,620,964	04-15-1997	Roth et al.	
	BK	us- 5,622,717	04-22-1997	Fuisz	
	BL	us- 5,637,320	06-17-1997	Bourke et al.	
	BM	us- 5,639,478	06-17-1997	Makino et al.	
	BN	us- 5,693,818	12-02-1997	Von Unge	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	CK	CA 1,129,417	08-10-1982	Junggren et al.		
	CL	CA 1,234,118	03-15-1988	Brandstrom et al.		
	CM	CA 1,263,119	11-12-1989	Kato et al.		
	CN	CA 1,264,751	01-23-1990	Brandstrom		
	CO	CA 1,292,693	12-03-1991	Lovgren et al.		
	CP	CA 1,302,891	06-09-1992	Lovgren et al.		
	CQ	CA 1,324,758	11-30-1993	Ruwart et al.		
	CR	CA 1,338,377	06-11-1996	Makino et al.		
	CS	CA 2,037,101	03-18-1997	Sik et al.		
	CT	CA 2,046,364	01-06-1993	Tanberk et al.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<div>Complete if Known</div> <div> <div>Application Number</div> <div>Not Yet Assigned</div> </div> <div> <div>Filing Date</div> <div>Concurrently Herewith</div> </div> <div> <div>First Named Inventor</div> <div>Chih-Ming Chen</div> </div> <div> <div>Art Unit</div> <div></div> </div> <div> <div>Examiner Name</div> <div></div> </div> <div> <div>Attorney Docket Number</div> <div>141-201B</div> </div>	
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				
Sheet	3	of	7	

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	CU	CA 2,083,605	12-08-1991	Brandstrom		
	CV	CA 2,139,653	12-08-1994	Lindberg et al.		
	CW	CA 2,140,347	02-03-1994	Nakanishi et al.		
	CX	CA 2,166,483	09-16-1997	Bengtsson et al.		
	CY	CA 2,166,794	03-04-1997	Kallstrom et al.		
	CZ	CA 2,170,647	01-25-1996	Bergstrand et al.		
	DA	CA 2,193,681	01-25-1996	Bengtsson et al.		
	DB	GB 1,234,058	06-03-1971	Kalman et al.		
	DC	EP 124,495	07-11-1984	Brandstrom		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Filing Date</td> <td>Concurrently Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Chih-Ming Chen</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>141-201B</td> </tr> </table>		Application Number	Not Yet Assigned	Filing Date	Concurrently Herewith	First Named Inventor	Chih-Ming Chen	Group Art Unit		Examiner Name		Attorney Docket Number	141-201B
Application Number	Not Yet Assigned														
Filing Date	Concurrently Herewith														
First Named Inventor	Chih-Ming Chen														
Group Art Unit															
Examiner Name															
Attorney Docket Number	141-201B														
Sheet	4	of	7												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	EA	L. Olbe, S.E. et al., Present Situation and Future Prospects of Medical Treatment., Gastrins and the Vagus, Academic Press p. 245-250, 1979.	
	EB	Ekenved et al. "Studies with H 168/68, a Novel Gastric Acid Secretion Inhibition., Gut, Vol. 22, p. A877, No. 10, October 1981.	
	EC	Erik Fellenius et al., Substituted Benzimidazoles Inhibit Gastric Acid Secretion by Blocking (H ⁺ + K ⁺) ATPase, Nature, Vol. 290, p. 159-161, March 12, 1981.	
	ED	Tore Lind, et al. Effect of Omeprazole - A Gastric Proton Pump Inhibitor on Pentagastrin Stimulated Acid Secretion in Man., Gut, Vol. 24 p. 270-276, 1983.	
	EE	K-Fr Sewin et al., Effect of Substituted Benzimidazoles on Acid Secretion in Isolated and Enriched Guinea Pig Parietal Cells., Gut, Vol. 24 p. 557-560, June 1983.	
	EF	Haken Larsson et al., Inhibition of Gastric Acid Secretion by Omeprazole in the Dog and the Rat. Gastroenterology, Vol. 85 p. 900-907, October 1983.	
	EG	Walter Londong et al. Dose-Response Study of Omeprazole on Meal Stimulated Gastric Acid and Gastrin Release., Gastroenterology, Vol. 85 p. 1373-1378, December 1983.	
	EH	Stanislaw J., Effects of Omeprazole, a Substituted Benzimidazole, on Gastrointestinal Secretions, Serum Gastrin and Gastric Mucosal Blood Flow in Dogs., Gastroenterology, Vol. 86 p. 71-77, January 1984.	
	EI	D.A. Henry et al., Omeprazole: Effects on Oxidative Drug Metabolism., British Journal of Clinical Pharmacology, Vol. 18, p. 195-200, August 1984.	
	EJ	B.K. Sharma et al. Optimal Dose of Oral Omeprazole for Maximal 24 Hour Decrease of Intragastric Acidity., Gut, Vol. 25, p. 957-964, September 1984.	
	EK	H.P.M. Festen et al., Effect of Oral Omeprazole on Serum Gastrin and Serum Pepsinogen I Levels., Gastroenterology, Vol. 87 p. 1030-1034, November 1984.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> Sheet 5 of 7		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Filing Date</td> <td>Concurrently Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Chih-Ming Chen</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>141-201B</td> </tr> </table>		Application Number	Not Yet Assigned	Filing Date	Concurrently Herewith	First Named Inventor	Chih-Ming Chen	Group Art Unit		Examiner Name		Attorney Docket Number	141-201B
Application Number	Not Yet Assigned														
Filing Date	Concurrently Herewith														
First Named Inventor	Chih-Ming Chen														
Group Art Unit															
Examiner Name															
Attorney Docket Number	141-201B														

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	EL	Peter Prichard et al. Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosages., Gastroenterology, Vol. 88, p. 64-69, January 1985.	
	EM	K.O. Borg and L. Olbe, Omeprazole - A Survey of Preclinical Data., Gastroenterology, p. 15-22, 37-51, 71-77, 79-93, 105-120, June 1985.	
	EN	50th Edition of Physician's Desk Reference p. 529-531, 1996.	
	EO	K.O. Borg, and L. Olbe, Proceedings of the First International Symposium on Omeprazole Supplement to the Scandinavian Journal of Gastroenterology, pp. 11-17, 31-38, 54-56, 59-60, 75-78, 89-135, 179, 182-183, 187-195, 1996.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.